Zemuron and Bladder mass - a phase IV clinical study of FDA data
Summary:
We study 1,504 people who take Zemuron (rocuronium bromide) or have Bladder mass. No report of Bladder mass is found in people who take Zemuron.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Zemuron?
Zemuron has active ingredients of rocuronium bromide. eHealthMe is studying from 873 Zemuron users. Check the latest studies of Zemuron.
What is Bladder Mass?
Bladder mass is found to be associated with 155 drugs and 193 conditions by eHealthMe. Check the latest studies of Bladder mass.
No report is found.
Do you take Zemuron and have Bladder mass?
- Check whether Bladder mass is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Zemuron:
- Zemuron (873 reports)
Bladder mass treatments and more:
- Bladder mass (631 reports)
How severe was Bladder mass and when was it recovered:
Expand to all the drugs that have ingredients of rocuronium bromide:
Browse all side effects of Zemuron:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Bladder mass:
Browse all the conditions that are associated with Bladder mass:
How the study uses the data?
The study uses data from the FDA. It is based on rocuronium bromide (the active ingredients of Zemuron) and Zemuron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Remodulin and Asthma for Women aged 30-39 - 10 seconds ago
- Remodulin and Exercise-Induced Asthma for Women aged 30-39 - 10 seconds ago
- Remodulin and Bronchial Asthma for Women aged 30-39 - 10 seconds ago
- Symbicort and Nosebleed for Men aged 40-49 - 11 seconds ago
- Remodulin and Chronic Asthma for Women aged 30-39 - 11 seconds ago
- Symbicort and Nose Bleed for Men aged 40-49 - 11 seconds ago
- Symbicort and Nose Bleeds for Men aged 40-49 - 11 seconds ago
- Symbicort and Epistaxis for Men aged 40-49 - 12 seconds ago
- Symbicort and Bleeding From The Nose for Men aged 40-49 - 12 seconds ago
- Symbicort and Nosebleeds for Men aged 40-49 - 12 seconds ago